Last reviewed · How we verify

Ivermectin Cream, 1% — Competitive Intelligence Brief

Ivermectin Cream, 1% (Ivermectin Cream, 1%) competitive landscape: 6 comparators, recent regulatory actions, upcoming PDUFA, patent timeline. Class: Antiparasitic agent. Area: Dermatology.

phase 3 Antiparasitic agent Glutamate-gated chloride channels (invertebrate-specific) Dermatology Small molecule Live · refreshed every 30 min

Target snapshot

Ivermectin Cream, 1% (Ivermectin Cream, 1%) — Actavis Inc.. Ivermectin binds to glutamate-gated chloride channels in parasites and arthropods, causing paralysis and death of the organisms.

Comparator set (6 drugs)

Auto-detected by same drug class / molecular target / therapeutic area, ranked by phase + recency. Override with ?vs=slug1,slug2,….

DrugGenericSponsorPhaseClassTargetApproval / PDUFA
Ivermectin Cream, 1% TARGET Ivermectin Cream, 1% Actavis Inc. phase 3 Antiparasitic agent Glutamate-gated chloride channels (invertebrate-specific)
''albendazole'' and ''ivermectin'' ''albendazole'' and ''ivermectin'' Centre d'Appui à la lutte contre la Maladie marketed Antihelmintic/Antiparasitic agents β-tubulin (albendazole); glutamate-gated chloride channels (ivermectin)
Ivermectin 1% cream (IVM) Ivermectin 1% cream (IVM) Galderma R&D marketed Antiparasitic agent Glutamate-gated chloride channels (invertebrate-specific)
Pyrimethamine (PYR) Pyrimethamine (PYR) Erasmus Medical Center marketed Antifolate antimalarial and antiparasitic agent Dihydrofolate reductase (DHFR)
Antimoniate of N-methylglucamine Antimoniate of N-methylglucamine University of Brasilia marketed Antiparasitic agent Leishmania glycolytic enzymes and mitochondrial function
Atovaquone Oral Suspension Atovaquone Oral Suspension University of Oxford marketed Antiparasitic agent Cytochrome bc1 complex (Complex III)
Ivermectin 1% cream Ivermectin 1% cream Insel Gruppe AG, University Hospital Bern marketed Antiparasitic agent Glutamate-gated chloride channels

Recent regulatory actions (last 90 days)

No regulatory actions in the last 90 days for this set.

Upcoming PDUFA dates (next 180 days)

No PDUFA dates in the next 180 days for this set.

Patent timeline (forward window)

No upcoming patent expiries for this set.

Sponsor landscape (Antiparasitic agent class)

  1. Actavis Inc. · 2 drugs in this class
  2. Galderma R&D · 1 drug in this class
  3. Insel Gruppe AG, University Hospital Bern · 1 drug in this class
  4. Padagis LLC · 1 drug in this class
  5. U.S. Army Medical Research and Development Command · 1 drug in this class
  6. University of Brasilia · 1 drug in this class
  7. University of Oxford · 1 drug in this class

Subscribe to ongoing alerts

Push every new event for this competitive set into your RSS reader, IFTTT/Zapier workflow, or email digest:

Cite this brief

Drug Landscape (2026). Ivermectin Cream, 1% — Competitive Intelligence Brief. https://druglandscape.com/ci/ivermectin-cream-1. Accessed 2026-06-10.

Build your own brief

Pick any drug + add comparators:

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing